EP3429584A4 - Compositions et méthodes de traitement de la presbytie - Google Patents
Compositions et méthodes de traitement de la presbytie Download PDFInfo
- Publication number
- EP3429584A4 EP3429584A4 EP17767172.4A EP17767172A EP3429584A4 EP 3429584 A4 EP3429584 A4 EP 3429584A4 EP 17767172 A EP17767172 A EP 17767172A EP 3429584 A4 EP3429584 A4 EP 3429584A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- presbyopia
- compositions
- treatment
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/073,089 US9844537B2 (en) | 2013-08-28 | 2016-03-17 | Compositions and methods for the treatment of presbyopia |
US15/073,139 US9833441B2 (en) | 2013-08-28 | 2016-03-17 | Compositions and methods for the treatment of presbyopia |
US15/235,431 US10052313B2 (en) | 2013-08-28 | 2016-08-12 | Compositions and methods for the treatment of presbyopia |
PCT/US2017/021244 WO2017160548A1 (fr) | 2016-03-17 | 2017-03-08 | Compositions et méthodes de traitement de la presbytie |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3429584A1 EP3429584A1 (fr) | 2019-01-23 |
EP3429584A4 true EP3429584A4 (fr) | 2019-11-13 |
Family
ID=59852351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17767172.4A Withdrawn EP3429584A4 (fr) | 2016-03-17 | 2017-03-08 | Compositions et méthodes de traitement de la presbytie |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3429584A4 (fr) |
JP (1) | JP2019508472A (fr) |
CN (1) | CN108883102A (fr) |
CA (1) | CA3017755A1 (fr) |
MX (1) | MX2018011300A (fr) |
WO (1) | WO2017160548A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11026884B2 (en) * | 2018-01-24 | 2021-06-08 | Eye Therapies Llc | Methods for improving vision |
US20190321334A1 (en) * | 2018-04-19 | 2019-10-24 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
EP4003341A4 (fr) * | 2019-07-26 | 2023-08-30 | Allergan Sales, LLC | Compositions et méthodes de traitement de la presbytie |
EP4236932A1 (fr) * | 2020-11-02 | 2023-09-06 | Visus Therapeutics, Inc. | Composé de dégradation dans un médicament |
CN114588156A (zh) * | 2022-04-22 | 2022-06-07 | 温州医科大学附属眼视光医院 | 一种眼用制剂及其在治疗老花眼中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160008278A1 (en) * | 2013-08-28 | 2016-01-14 | Presbyopia Therapies, LLC | Compositions and Methods for the Treatment of Presbyopia |
US20160346259A1 (en) * | 2013-08-28 | 2016-12-01 | Presbyopia Therapies, LLC | Compositions and Methods for the Treatment of Presbyopia |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6120758A (en) * | 1998-07-16 | 2000-09-19 | Shaklee Corporation | Preservative system for topically applied products |
US9314427B2 (en) * | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
WO2015094392A1 (fr) * | 2013-12-18 | 2015-06-25 | Gnt, Llc | Compositions et méthodes destinées à traiter le glaucome |
-
2017
- 2017-03-08 EP EP17767172.4A patent/EP3429584A4/fr not_active Withdrawn
- 2017-03-08 CN CN201780017733.8A patent/CN108883102A/zh active Pending
- 2017-03-08 MX MX2018011300A patent/MX2018011300A/es unknown
- 2017-03-08 JP JP2018548865A patent/JP2019508472A/ja active Pending
- 2017-03-08 WO PCT/US2017/021244 patent/WO2017160548A1/fr active Application Filing
- 2017-03-08 CA CA3017755A patent/CA3017755A1/fr not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160008278A1 (en) * | 2013-08-28 | 2016-01-14 | Presbyopia Therapies, LLC | Compositions and Methods for the Treatment of Presbyopia |
US20160346259A1 (en) * | 2013-08-28 | 2016-12-01 | Presbyopia Therapies, LLC | Compositions and Methods for the Treatment of Presbyopia |
Non-Patent Citations (1)
Title |
---|
See also references of WO2017160548A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA3017755A1 (fr) | 2017-09-21 |
MX2018011300A (es) | 2019-02-18 |
JP2019508472A (ja) | 2019-03-28 |
CN108883102A (zh) | 2018-11-23 |
EP3429584A1 (fr) | 2019-01-23 |
WO2017160548A1 (fr) | 2017-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3675882A4 (fr) | Methodes et compositions pour le traitement de troubles associés au microbiome | |
EP3347469A4 (fr) | Méthodes et compositions pour le traitement du glaucome | |
EP3426250A4 (fr) | Procédés de traitement | |
EP3177732A4 (fr) | Compositions et procédés pour le traitement de maladies et états pathologiques ophthalmiques | |
EP3038610A4 (fr) | Compositions et méthodes pour le traitement de la presbytie | |
EP3183005A4 (fr) | Méthodes et compositions destinées au traitement de troubles métaboliques | |
EP3408344A4 (fr) | Procédés et compositions de traitement de puits | |
EP3423100A4 (fr) | Compositions destinées à traiter l'inflammation et méthodes de traitement associées | |
EP3538189A4 (fr) | Compositions, dispositifs et méthodes pour le traitement de conditions médiées par un récepteur des opioides | |
EP3429584A4 (fr) | Compositions et méthodes de traitement de la presbytie | |
EP3352749A4 (fr) | Composés et compositions pour le traitement de troubles oculaires | |
EP3863630A4 (fr) | Compositions et procédés pour le traitement de la presbytie | |
EP3651747A4 (fr) | Compositions et méthodes de traitement de troubles oculaires | |
EP3720421A4 (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
EP3310783A4 (fr) | Procédés et compositions de prévention et de traitement de la perte d'audition | |
EP3687524A4 (fr) | Compositions et méthodes de traitement de troubles ophtalmiques | |
EP3094284A4 (fr) | Compositions et méthodes pour le traitement d'une néovascularisation et/ou d'une fuite intraoculaire | |
EP3522873A4 (fr) | Compositions et méthodes pour le traitement de la xérostomie | |
EP3368048A4 (fr) | Méthodes et compositions pour le traitement de l'amyloïdose | |
IL272121A (en) | Preparation and methods for the treatment of myopia | |
EP3185910A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
EP3452044A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
EP3491129A4 (fr) | Procédés de traitement de l'osmidrose | |
EP3341006A4 (fr) | Compositions et méthodes pour le traitement d'une lésion neurologique | |
ZA201900984B (en) | Methods and compositions for the treatment of warts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180906 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20191010 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/439 20060101AFI20191004BHEP Ipc: A61K 47/38 20060101ALI20191004BHEP Ipc: A61P 27/10 20060101ALI20191004BHEP Ipc: A61K 9/00 20060101ALI20191004BHEP Ipc: A61K 31/4409 20060101ALI20191004BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200603 |